MACIVIVA is the acronyme for the project “Manufacturing process for Cold chain Independent Virosome-based Vaccines”. It is an European project of 42 months, involving 6 partners: Mymetics BV (from The Netherlands), Mymetics SA and Bachem AG (from Switzerland), Upperton and Catalent (from United Kingdoms), Chimera Biotech GmbH (Germany).
This innovative European project brings together world class expertise from well-established SMEs in the field of virosome vaccines, drug formulations, spray drying, immunomonitoring assays, together with world-leading CMOs with freeze drying expertise, large scale manufacturing and packaging capabilities.
MACIVIVA consortium will:
- Explore new galenic vaccine formulations and stabilization methods allowing Good Manufacturing Practices (GMP) and up-scaling of new virosome-based vaccines.
- Transform liquid to solid form virosome-based vaccines for needle-free vaccination through non-invasive routes, such as sublingual, oral and nasal delivery for better acceptance by the population.
- Develop cold-chain independent and thermostable virosomal vaccines.
European Members States (The Netherlands, United Kingdom and Germany) of this project are received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 646122.
Swiss Partners are supported by the Swiss government: The State Secretariat for Education, Research and Innovation (SERI) within the Federal Department of Economic Affairs, Education and Research (EAER).
Posted by maciviva
Thanks to a Horizon 2020 grant, 6 biotech companies are pool- ing their expertise to develop solid-form, thermostable vaccines that will be cheaper,…Read More Posted in News
Posted by maciviva
Chimera Biotec Awarded Grant to Support Ultra Sensitive Efficacy Testing of an Oral and Nasal Vaccine Delivery Platform. Dortmund, Germany – 29th May,…Read More Posted in News